Literature summary for 3.4.21.6 extracted from

Turpie, A.G.; Bauer, K.A.; Davidson, B.L.; Fisher, W.D.; Gent, M.; Huo, M.H.; Sinha, U.; Gretler, D.D.; Gretler, D.D.
A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT) (2009), Thromb. Haemost., 101, 68-76.

Search for more literature for 3.4.21.6

Application

Application	Comment	Organism
pharmacology	treatment of patients undergoing elective total knee replacement post-operatively with betrixaban or enoxiparin for 10-14 days to prevent thromboembolism. Betrixaban shows a dose- and concentration-dependent effect on inhibition of thrombin generation and anti-factor Xa levels. Betrixaban demonstrates antithrombotic activity and is well tolerated in knee replacement patients	Homo sapiens

Inhibitors

Inhibitors	Comment	Organism	Structure
betrixaban	-	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	patients undergoing elective total knee replacement	-

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)